Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 3,303 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Not applicable Interventional Results available

1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma

NCT01541644
View directory record Official record
Conditions
Peripheral Neuropathies, Multiple Myeloma
Interventions
Acupuncture
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 15, 2026, 11:50 AM EDT
Not listed Not applicable Interventional

Clinical Study of Abdominal Aortic Aneurysm Exclusion (TALENT Abdominal)

NCT00549432
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
TALENT Enhanced LPS Endoluminal Stent-Graft System
Device
Lead sponsor
Arizona Heart Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2009 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 15, 2026, 11:50 AM EDT
Not listed Early Phase 1 Interventional

Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia

NCT04816799
View directory record Official record
Conditions
Stroke, Aphasia, Apraxia of Speech
Interventions
Startle Adjuvant Rehabilitation Therapy (START)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 15, 2026, 11:50 AM EDT
Completed No phase listed Observational

Levels of Inflammatory Markers in the Treatment of Stroke-An SPS3 Ancillary Study

NCT00579306
View directory record Official record
Conditions
Hypertension, Stroke
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
30 Years and older
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, Levofloxacin
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00962507
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 15, 2026, 11:50 AM EDT
Active, not recruiting Not applicable Interventional

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

NCT02009644
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Subjects who receive the Treovance stent-graft
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Danbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Not applicable Interventional

The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of Intraventricular Hemorrhage (IVH)

NCT05113381
View directory record Official record
Conditions
Intraventricular Hemorrhage, Subarachnoid Hemorrhage
Interventions
CerebroFlo™ EVD Catheter
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 15, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional

PHA-739358 for the Treatment of Multiple Myeloma

NCT00872300
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PHA-739358
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

NCT00001221
View directory record Official record
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
Growth Hormone (Humatrope)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 11:50 AM EDT
Not listed Phase 3 Interventional

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

NCT01824407
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Electrohydraulic-generated shock wave, Sham device plus standard of care
Device
Lead sponsor
SANUWAVE, Inc.
Industry
Eligibility
22 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 15, 2026, 11:50 AM EDT
Recruiting No phase listed Observational

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

NCT06837181
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions
observational study
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)

NCT01275092
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
CorPath robotic-assisted PCI
Device
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Gainesville, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

NCT00721136
View directory record Official record
Conditions
Bradycardia, Tachycardia, Atrial Fibrillation, Valvular Heart Disease
Interventions
continue warfarin through the procedure, Hold warfarin, Warfarin held with heparin transition.
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 15, 2026, 11:50 AM EDT
Active, not recruiting Not applicable Interventional Results available

LIFE-BTK Randomized Controlled Trial

NCT04227899
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
Esprit BTK Device, Percutaneous Transluminal Angioplasty (PTA) Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Deer Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 15, 2026, 11:50 AM EDT
Recruiting Early Phase 1 Interventional

Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain

NCT07260656
View directory record Official record
Conditions
Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions
Capsaicin Palmitate, Placebo
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Recruiting Not applicable Interventional

Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

NCT07364630
View directory record Official record
Conditions
Diabetic Foot Ulcer, Foot Ulcer Chronic, DFU, Ulcer Foot, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, Leg Ulcers, Ulcer
Interventions
Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU
Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philidelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01962792
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ibrutinib, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 15, 2026, 11:50 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT02394912
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
vena cava filter implantation (LUMIFI with Crux VCF System)
Device
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Orangeburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 15, 2026, 11:50 AM EDT
Recruiting No phase listed Observational

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

NCT06193928
View directory record Official record
Conditions
Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions
Livmarli
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

NCT00661544
View directory record Official record
Conditions
Multiple Myeloma, Stem Cell Transplantation
Interventions
Arsenic Trioxide, Melphalan, Ascorbic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 15, 2026, 11:50 AM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 11:50 AM EDT